![Dual-antigen targeting in AML with chimeric receptors enhances specificity and efficacy of engineered T cells. Schematic of the approach. AbTCR, chimeric receptor using the fragment antigen binding (Fab) region of an ESK2 antibody recognizing the WT1 (RMF [RMFPNAPYL]) peptide/HLA-A∗02:01 complex linked to the Cγ and Cδ regions of the γδ T-cell receptor (TCR). CSR, chimeric costimulatory signaling receptor using a single-chain variable fragment (scFv) recognizing CD33 linked to parts of the CD28 costimulatory molecule. Box: overall outcome of the approach engineering T cells with AbTCR + CSR.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/143/6/10.1182_blood.2023023004/1/blood_bld-2023-023004-c-gr1.jpeg?Expires=1735804119&Signature=Kucs1YZeasoyl6WSS~~A9CIzeA9SMHFiSxPiGCbZ0hZHzaZLBF7hBwmtgYA3R~S~dl-o8uZKt8jc7GYkcfbItqPjdIQDgKi0MJgZtuQ0uHnJFt5bfHt5EpQYEzCoxjq7QbYP08G9R~6MkykClHaVx70WydZEytXpJOmSKFhgFJks70dgeCEvXViEui89Sj3DGd8U15rSYoKy9PzrCdEQaZXXPMw~vxBKkMEWvFdW5Yd9~rNesANGTMMEiOI0n2rwk3NiHYDuUS-EltYTSBew5vn7LPuZ6BklhGq9wxhnWbenRQIUzqIFju5V4Vdmtqg~ETC2ih0skUKjqX-~Uy1OSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Dual-antigen targeting in AML with chimeric receptors enhances specificity and efficacy of engineered T cells. Schematic of the approach. AbTCR, chimeric receptor using the fragment antigen binding (Fab) region of an ESK2 antibody recognizing the WT1 (RMF [RMFPNAPYL]) peptide/HLA-A∗02:01 complex linked to the Cγ and Cδ regions of the γδ T-cell receptor (TCR). CSR, chimeric costimulatory signaling receptor using a single-chain variable fragment (scFv) recognizing CD33 linked to parts of the CD28 costimulatory molecule. Box: overall outcome of the approach engineering T cells with AbTCR + CSR.
